trimetrexate has been researched along with Central Nervous System Toxoplasmosis in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Masur, H | 1 |
| Polis, MA | 1 |
| Tuazon, CU | 1 |
| Ogata-Arakaki, D | 1 |
| Kovacs, JA | 1 |
| Katz, D | 1 |
| Hilt, D | 1 |
| Simmons, T | 1 |
| Feuerstein, I | 1 |
| Lundgren, B | 1 |
1 other study available for trimetrexate and Central Nervous System Toxoplasmosis
| Article | Year |
|---|---|
Salvage trial of trimetrexate-leucovorin for the treatment of cerebral toxoplasmosis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Drug Evaluation; Female; Humans; Leucovorin; | 1993 |